The key facts about the biomanufacturing sector
👉 Unveil reveals the contents of biomedical nanoparticle drugs
Unveil, a start-up from Paris-Saclay University and winner of the i-Lab 2025 prize, has developed a technology capable of analyzing the contents of nanoparticles used to protect the active ingredients in biomedical drugs. " The ratio of full to empty capsules has become an essential criterion for judging the effectiveness of a production process,“ co-founder Alexis Auchère explains to Les Echos. ”Our device is very easy to use and will make testing routine." Compact, it delivers a diagnosis in five minutes from a single drop from a bioreactor, compared to several hours with conventional methods.
👉 Immerscio.bio and the IMT Group are betting on immersion in bioproduction
Immerscio.bio and the IMT Group have announced a partnership to create hybrid training courses in bioproduction, combining immersive digital tools and practical experience in factory-schools. “France is gradually gaining visibility in Europe and internationally, particularly in the field of biotherapies and new technologies,” says Sandrine Lemoine, co-founder of Immerscio.bio. “But the real challenge remains industrialization” and training for bioproduction professions that are “complex and very different from those in traditional pharmacy or chemistry,” adds Hervé Galtaud, CEO of the IMT Group. The first two training courses will be launched by the end of 2025: non-compliance management and technology transfer.
👉 Bioproduction stakeholders gather in Frankfurt
The annual Conference on Pharmaceutical Ingredients (CPHI) opened its doors in Frankfurt until October 30. With 62,000 participants expected and 2,400 exhibitors from 166 countries, this event is an opportunity for laboratories to meet their suppliers and take stock of innovation in production. The conferences focus on the future of drug development, artificial intelligence (AI), digital transformation, and sustainability, key themes that determine how biopharmaceutical technologies are developed, scaled up, and delivered worldwide. “The 2025 event reflects not only the scale of innovation in the biopharmaceutical sector, but also the sector's need for connected leadership and diverse perspectives,” said Tara Dougal, director of the event.